A Phase III, open label, randomized, controlled, multicenter study to assess the safety and efficacy of the Study Drug monotherapy versus the physician’s choice to treat platinum-sensitive relapsed ovarian cancer.
Explore related content and topics
Blog
Much More Than a Single Clinical Trial
Delivering drugs to the patients who need them can be an increasingly complex, time-consuming, and costly undertaking, particularly for smaller…
Read Story
resource
The Future of Clinical Trials: Connected and Virtual Approaches for Rare Diseases
Scott Schliebner, Senior Vice President, Center for Rare Diseases at PRA Health Sciences talks about how amore patient-centred approach is needed to…
View Resource
Newsletter
RARE DISEASES NEWSLETTER Volume 17, July 2020
Welcome to the seventeenth edition of the rare disease newsletter. A few months has changed the world of clinical research into a very different…
View Resource
View all related content and resources for Study Design
Explore Insights